Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

McKesson Corp (NY: MCK )

515.24 -10.68 (-2.03%)
Streaming Delayed Price Updated: 1:35 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about McKesson Corp

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,200 Today
Via Benzinga
Top Stock Reports For Apple, Nvidia & Eli Lilly
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., NVIDIA Corporation, and Eli Lilly and Company. 
Via Talk Markets
Peering Into McKesson's Recent Short Interest
Via Benzinga
Rite Aid Forges Path To Financial Recovery With Major Settlement: Report
Rite Aid (OTC: RADCQ) settles with lenders and DOJ, marking a crucial step toward bankruptcy resolution by April, Reuters reports. Attorney Aparna Yenamandra highlights broad stakeholder agreement,... 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
How Is The Market Feeling About McKesson?
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,900 Today
Via Benzinga
Which Stocks Will Dominate The Future Of Tech? UBS Shares Its Top Picks In AI, Healthtech, Greentech, And Fintech
In a recent report, global wealth manager UBS has identified the sectors that are likely to drive the next wave of technological innovation and the stocks that stand to benefit. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation
FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices. 
Via Benzinga
3 Attractive Medical Stocks To Buy After Earnings
Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare... 
Via Talk Markets
Medical Supplies-Focused McKesson Shares Fall On Q3 Earnings Performance, Analyst Says Street 'Wanted More'
McKesson beats expectations with Q3 2024 sales of $80.9 billion, up 15%. U.S. Pharmaceutical Segment thrives, adjusted EPS at $7.74, exceeding consensus. 
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
Earnings Preview: McKesson
Via Benzinga
Here's How Much $1000 Invested In McKesson 5 Years Ago Would Be Worth Today
Via Benzinga
Peering Into McKesson's Recent Short Interest
Via Benzinga
McKesson (MCK) Q3 2024 Earnings Call Transcript
MCK earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments... 
Via Benzinga
Topics Stocks
Exposures US Equities
McKesson Earnings Are Imminent; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
McKesson Corporation (NYSE: MCK) is expected to release earnings results for its third quarter, after the closing bell on Feb. 7, 2024. 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $12,000 Today
Via Benzinga
Check Out What Whales Are Doing With MCK
Via Benzinga
How Is The Market Feeling About McKesson?
Via Benzinga
Here's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years
Via Benzinga
Fear & Greed Index Remains In 'Greed' Zone Following Earnings Reports; Dow Jumps Over 100 Points
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed higher on Tuesday, as... 
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 3
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 29 through Feb. 2. 
Via Talk Markets
3 Hidden Healthcare Stocks Poised for a Breakout This Year
As the market preferences start to switch toward stable and defensive names like healthcare, these stocks could help your portfolio. 
Via InvestorPlace
Exceeding Expectations: McKesson Achieves Strong Performance and Rewards Investors
On January 02, 2024, McKesson (NYSE:MCK) will distribute a dividend payout of $0.62 per share, equating to an annualized dividend yield of 0.55%. Shareholders who owned the stock before the ex-dividend... 
Via Benzinga
Silver Economy Successes: 3 Stocks Benefitting From an Aging Population
Explore our in-depth analysis of aging population stocks, uncovering the opportunities and challenges in this sector. 
Via InvestorPlace
Topics Economy
Exposures Economy
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.